Pfizer-BioNTech to get European Union 200 million more Covid-19 shots

The firms reached an agreement to supply the European Union with another 200 million doses of their Covid-19 vaccine

Pfizer, coronavirus vaccine
Pfizer | File photo
AP | PTI Berlin
1 min read Last Updated : Feb 17 2021 | 4:04 PM IST

Pfizer and BioNTech said Wednesday they have reached an agreement to supply the European Union with another 200 million doses of their COVID-19 vaccine.

The US and German companies said in a statement that the doses come on top of the 300 million initially ordered. The EU's executive Commission has an option to request a further 100 million doses.

They said the 200 million doses are expected to be delivered this year, with an estimated 75 million of them in the second quarter.

The Pfizer-BioNTech vaccine was the first of three so far to be approved for use in the EU, which faces criticism for a slow start to its vaccination campaign. The other two approved vaccines are from Moderna and AstraZeneca.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Feb 17 2021 | 3:58 PM IST

Next Story